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 ABSTRACT                                                                                                                                            
L–Carnitine ameliorates the iron mediated DNA 
degradation in peripheral leukocytes of β- thalassemic 
children.
Seham M. Ragab1 and Riham G.Mahfouz2
1Departments of Pediatrics and 2Biochemistry, Faculty of Medicine, Menoufiya 
University, Egypt.
Background: Iron overload is a common complication in β-thalassemia that 
induces intracellular oxidative stress producing lesions in the DNA including 
double strand breaks. 
Objectives: The aim of this study was to evaluate DNA damage in peripheral 
leukocytes of β -thalassemic children and to investigate its association with the iron 
overload and the role of L-carnitine therapy upon this damage. 
Subjects and Methods: Fifty β-thalassemic children (25 TM and 25 TI) with 
20 age and sex matched apparently healthy children (control group) were 
included. Serum ferritin level was measured by ELISA. DNA damage was 
evaluated by the Gel electrophoresis to determine the total DNA genomic 
damage (TGD). The intensity of DNA nucleoprotein was measured by software 
Gel Pro analyzer computer program as maximum optical density (max.O D) 
values of apoptotic fragments of DNA at 200bp, 400bp and 600bp. 
Results: The smear shape pattern on gel electrophoresis and Pro-Gel analyzer 
chart indicating double strand breakage of the DNA was detected in 76% of the 
thalassemic children. The thlassemic patients (the whole group and each of TM 
and TI groups) had significantly higher prevalence of DNA double -strand breaks 
in their leukocytes with significant higher values of max. OD at 200,400and 
600 bp compared to the control group. The thalassemic children on regular 
L-carnitine therapy (50mg/kg/d for at least 6 months) had significantly lower 
prevalence and degrees of DNA breaks (TGD) with significant lower max. OD 
values at 200,400 and 600 bp compared to those not on L-carnitin therapy. 
There was significant positive correlation between the mean serum ferritin 
levels and the values of max. OD at 200 and 400bp. The data obtained from 
the Roc Curve shows that, the best sensitivity of 95% and specificity of 75% 
for the mean serum ferritin were at the cut off point of 820 ng/ml to predict the 
occurrence of TGD in thalassemic leukocytes. 
Conclusions: Thalassemic children had significant DNA double-strand breaks 
in their leukocytes that was positively correlated to their iron overload reflected 
by serum ferritin level and can be ameliorated by L-carnitine supplementation.
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INTRODUCTION                                                                     
β-Thalassemia is a hereditary anemia 
resulting from defects in the production 
of β-globin chains1. In β-thalassemia, 
various mutations result in absence (βo) 
or reduced (β+) synthesis of β-globin 
chains. Consequently, the relative ex-
cess of β-globin chains forms unstable 
tetramers which cause cellular dam-
age2. Depending on clinical severity, 
two forms are distinguished, namely, 
thalassecmia major (TM) and thalasse-
mia intermedia (TI).3
The oxidative status of cells is deter-
mined by the balance between pro-ox-
idants and antioxidants. Pro-oxidants, 
referred to as reactive oxygen species 
(ROS), are classified into radicals and 
non-radicals. ROS, when are generated 
in excess, may oxidize proteins, lipids 
and DNA-leading to cell death and or-
gan damage. Oxidative stress is believed 
to aggravate the symptoms of many dis-
eases, including hemolytic anemias.4
Chronic iron overload is currently 
considered to be the primary cause of 
morbidity and mortality of thalassemic 
patients. It results from a number of 
mechanisms associated with the disease 
itself. These mainly include ineffective 
erythropoiesis, peripheral hemolysis, 
increased intestinal iron absorption as 
well as repetitive blood transfusion5. 
In situations of iron excess, the iron-
binding capacity of transferrin is satu-
rated, resulting in the appearance of 
non-transferrin-bound iron (NTBI) in 
the plasma6. The toxicity of NTBI is 
attributed to its ability to catalyze free-
radical reactions that have life-threaten-
ing consequences7. Iron could catalyze 
the oxidative breakdown of most bio-
molecules such as lipids, sugars, amino 
acids, DNA etc8. Iron-mediated lipid 
peroxidation, depletion of low-molecu-
lar weight antioxidants and single- and 
double-strand breaks in DNA have been 
implicated in the pathophysiology of 
iron overload diseases9. In humans, iron 
overload correlates with DNA altera-
tions and cancer10,11. In thalassaemia pa-
tients, the high level of iron means that 
free radical generation is accessible, 
through Fenton-type chemistry. There-
fore, these patients are particularly at 
risk of free radical induced damage in-
cluding DNA strand breakage.12   
In the treatment of thalassemia, newer 
approaches have been tried as alterna-
tive to standard therapy. Butyrate ana-
logues such as L-carnitine have been 
found to increase HbF synthesis and 
hence used in treatment of β- thalasse-
mia13. L-carnitine plays an essential role 
in fatty acid oxidation in mitochondria 
and energy production14. It also protects 
erythrocytes from oxidative stress, sta-
bilizes the cell membrane, increasing 
the life span of red blood cells and is 
found to inhibit apoptosis in different 
diseases15. L-carnitine is a free radical 
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scavenger which prevents lipid peroxi-
dation of cell membrane and apoptosis 
reducing serious tissue damage.16
The objectives of the present study were 
to evaluate DNA damage in peripheral 
leukocytes of β -thalassemic children 
and to investigate its association with 
the iron overload and the role of L-car-
nitine therapy upon this damage.
SUBJECTS AND METHODS                                   
Subjects: This study included 50 β -thal-
assemic children regularly attending the 
pediatric hematology clinic in Menou-
fiya University Hospital for transfu-
sion and chelation (25TM and 25TI). 
They were 25 males and 25 females 
aged 3-19 years (mean 9.7±4.44 years). 
Regarding TM patients they were 12 
males and 13 females aged 3-19 years 
(mean 8.69±5.2 years). These patients 
were treated to maintain the pre-trans-
fusion Hb level above 8 g/dl and post-
transfusion Hb above 10 g/dl by regular 
red blood cell concentrates transfusion. 
Thalassemia intermedia (TI) were 25 
patients who regularly attend our he-
matology clinic for follow up and blood 
transfusion when needed. They were13 
males and 12 females aged 4-18 years 
(mean 10.44±3.38 years). Twenty on 
transfusion (every one or two months) 
to maintain their growth and 5 were oc-
casionally transfused. Twenty patients 
of TM group were under regular che-
lation by Desferroxamine (DFO) and 5 
did not need to start the chelation yet. 
Of TI patients, 19 patients were regular-
ly chelated by DFO and 6 did not need 
to start the chelation therapy.
To demonstrate the role of L-carnitine 
therapy, the study group was selected 
to involve a subgroup of patients under 
regular compliant L - carnitine therapy 
(50 mg/kg/day) for at least 6 months. 
This group included 10 TM and 10 TI 
patients.
Twenty age and sex matched apparent-
ly healthy children were enrolled as a 
control group. They were 9 males and 
11 females aged 3 to 18 years (mean 
9.1±3.79 years). Their Hb levels ranged 
from 12.0 to 14 g/dl (mean 13±0.5g/dl). 
All participants and their parents are 
informed with the study that was ap-
proved by the Ethics Committee.
Methods 
Each participant was subjected to, full 
history taking and thorough clinical ex-
amination.
The mean yearly serum ferritin level in 
the previous year was considered (on 
the average of 3 determinations) for 
each patient. Serum ferritin was mea-
sured by Enzyme Linked Immune Sor-
bent Assay (ELISA) technique. Serum 
was prepared from a whole blood speci-
men without additives avoiding grossly 
hemolytic, lipemic, or turbid samples. 
Specimens were capped and stored 
frozen at 2-80 C till the time of the as-
say. 20μl of standard, sample or control 
were pipetted and added to 100μl of En-
zyme Conjugate Reagent into all wells 
and thoroughly mixed for 30 seconds 
then incubated for 45 minutes at room 
temperature. Supernatant was decanted, 
washed 5 times with distilled or dion-
ized water. 100μl of tetramethyl benzi-
dine (TMB) Reagent were incubated for 
20 minutes at room temperature in the 
dark. 100μl of the stop solution were pi-
petted and mixed gently for 30 seconds 
till the blue color changed completely 
to yellow. Absorbance was read at 450 
nm within 15 minutes. 
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DNA fragmentation assay:
The blood sample was drown before 
blood transfusion. An amount of 1 ml 
of whole blood was incubated with 8 
ml of (ELB). This is composed of 0.8 
g ammonium chloride, 0.12 g sodium 
bicarbonate and 0.06 g EDTA dissolved 
in 100 ml distilled water. The blood 
was incubated for 10 minutes at 370 C. 
It was then centrifuged for 5 minutes 
at 1000 rpm. This step was repeated 
twice till a white pellet appeared17. The 
platelets were removed carefully. The 
leukocyte pellet was washed twice with 
RPMI 1640 medium, supplemented 
with 10% fetal bovine serum. The leu-
cocytes were distributed in 15 ml steril-
ized falcon tubes at appropriate concen-
tration (5x105 cells/ml) for treatment. 
DNA was extracted from both control’s 
and patient’s leukocytes based on salt-
ing out extraction methods according 
to the method of Al-Janabi and Marti-
nez18. whereas protein was precipitated 
by saturated solution of NaCl, (5M).
Isolated leucocytes in eppendorf tubes 
were lysed by 600 microliter lysing 
buffer (50 mM NaCl, 1mM Na2 EDTA, 
10% SDS pH 8.3) and was shaken gen-
tly. The mix was kept overnight at room 
temperature. For protein precipitation, 
an amount of 200 microliter of saturated 
NaCl was added to the samples and was 
gently shaken and centrifuged at 12,000 
rpm for 10 minutes. The supernatant 
was transferred to new eppendorf tubes 
and the DNA was precipitated by 600 
microliter cold iso-propanol. The mix 
was inverted several times till fine fi-
bers of nucleic acids appeared and cen-
trifuged for 5 minutes at 12,000 rpm. 
The supernatant was then removed. For 
washing, an amount of 500 microliter 
of 70% ethyl alcohol was added to pel-
let and decanted or tipped and the tubes 
blotted on whatman paper or clean tis-
sue for 15 minutes. When the tubes 
were seen to dry, the pellets were re-
suspended in 50 microliter volume of 
TE buffer (10mM tris, 1 mM EDTA, 
pH 8) supplemented with 5% glycerol, 
gently pipetted and RNA was digested 
with Rnase for 1 hour. 
Gel was prepared with 1.8% electro-
phoretic grade agarose (BRL). The 
agarose was boiled with tris -borate 
EDTA buffer (1 x TBE; 89 mM Tris, 89 
mM boric acid, 2mM EDTA, pH 8.3). 
0.5 microgram/ml ethidium bromide 
was added to the gel at 400C. Gel was 
poured and allowed to solidify at room 
temperature for 1 hour before samples 
were loaded.19
Gel Electrophoresis: Electrophoresis 
was performed for 2 hours at 50 volt 
in gel buffer (1 X TBE buffer) at room 
temperature with buffer level 2 mm cov-
er the gel. Gel was photographed using 
a Polaroid camera while the DNA was 
visualized using a 312 nm UV trans-
illuminator20. Electrophoresis pattern of 
nucleic acids determined total genomic 
damage (TGD) of DNA. The intensity 
of DNA nucleoprotein was measured 
by software Gel Pro- analyzer comput-
er program (Ver 3.1). Apoptotic bands 
were located at 200 bp and its mul-
tiples. The intensity of apoptotic bands 
could be measured by Gel-Pro program 
as maximum optical density (Max.O D) 
values of apoptotic fragments of DNA 
at 200bp, 400bp and 600bp. The charts 
pattern denotes and confirms the degree 
of this total genomic damage (Fig. 1).
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Statistics: Results were collected, tab-
ulated, statistically analyzed by IBM 
personal computer and Statistical Pack-
age for Social Sciences (SPSS) version 
16. Differences between and within the 
groups were evaluated by the non-para-
metric Mann-Whitney test. Chi-square 
test (χ2) was used to study the rela-
tion between two qualitative variables. 
Pearson correlation (r): Is a test used to 
measure the association between two 
quantitative variables. Bivariate lin-
ear regression analysis test was used 
to study the power of certain risk fac-
tor. Receiver Operating Characteristic 
curve analysis (ROC curve) is a graph 
of sensitivity against 1- specificity at 
different cutoff points. The optimal 
cutoff point is that gives the highest 
sensitivity and specificity. P-value of 
<0.05 was considered statistically sig-
nificant.21
RESULTS                                                                       
The results of this study revealed that 
the mean yearly serum ferritin (ng/ml) 
was significantly higher in thalassemic 
children (as a whole) and in each of 
thalassmic groups (TM and TI) com-
pared to the control group. There was 
no significant difference regarding the 
mean yearly serum ferritin between 
thalassemia major compared to thalas-
semia intermedia patients or between 
thalassemic patients on and those not 
on L-carnitine therapy (Table 1). Re-
garding the DNA damage, all children 
of the control group had normal electro-
phoretic pattern that was confirmed by 
normal charts of Pro-Gel analyzer pro-
gram. No one of the control or the stud-
ied thalassemic children had the ladder 
pattern of apoptotic DNA damage. The 
smear shape pattern on gel electropho-
resis indicating double -strand breakage 
of the DNA confirmed by the chart pat-
tern of Pro-Gel analyzer was the main 
finding among thalassemic children (in 
76%) mainly in the moderate and se-
vere forms (Fig. 2). The thlassemic pa-
tients (the whole group and each of TM 
and TI Group) had significantly higher 
prevalence of DNA double -strand 
Fig. 1: Chart Patterns of DNA damage in the Gel –Pro analyzer.
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breaks in their leukocytes demonstrated 
by the gel electrophoresis and Pro-Gel 
analyzer charts with significant higher 
values of max. O D at 200, 400 and 
600 bp compared to the control group. 
There was no significant difference be-
tween TM and TI patients regarding the 
pattern of DNA double -strand break-
age or the max. O D values at 200, 400 
and 600 bp. The thalassemic children 
on regular L-carnitine therapy had sig-
nificantly lower prevalence and degrees 
of DNA breaks (TGD) with significant 
lower max. O D values at 200, 400 and 
600 bp compared to those not on L-
carnitine therapy (Table 1). There was 
significant positive correlation between 
the mean serum ferritin levels and the 
values of max. O D at 200 and 400bp 
(Fig 3) without significant correlation 
to that at 600bp. The bivariate linear re-
gression revealed that the mean serum 
ferritin predicted the value of max. OD 
at 200bp at B= 0.66 (P <0.001) while it 
was found to predict the value of max.
OD at 400bp at B= 0.43 (P= 0.002). 
The data obtained from the Roc Curve 
shows that, the best sensitivity of 95% 
and specificity of 75% for the mean se-
rum ferritin were at the cut off point of 
820 ng/ml to predict the occurrence of 
TGD in thalassemic leukocytes, while 
at cutoff point of 980 ng/ml serum fer-
ritin had sensitivity of 76% and speci-
ficity of 81% for DNA damage (Fig 4). 
Fig. 2: Gel electrophoresis of some studied thalassemic patients and some control children.
M= Molecular weight marker.
Lanes 1, 2 and 3show intact DNA. Lane 1 for thalassemic child on L-carnitine therapy while lanes 2 and 
3 for normal control children.
Lanes 4, 5, 6, 7, 9 and 10 show smear –shaped DNA damage of severe degree for thalassemic patients 
not on L-carnitin therapy.
Lane 8 shows smear shaped DNA damage of moderate severity for thalassemic patient not on L-carnitine 
therapy.
Lane 11 shows smear shaped DNA damage of mild severity for thalassemic patient on L-carnitine therapy.
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Fig. 4: The histogram represents the sensitivity and specificity of serum ferritin  at  different  cut off 
points.
Fig. 3: Bivariate linear regression shows signifigant positive correlation between serum ferritin level 
and the max. OD at 200 and 400bp.
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Table 1: Comparison between different groups regarding clinical characteristics, serum ferritin level, 
pattern of Electrophoretic DNA damage and maximum optical density values (Max.O D) of apoptotic 
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*= Significant.  
1= Normal curve pattern.                                     2= Mild DNA damage  pattern.         
3= Moderate DNA damage pattern.                     4= Severe DNA damage pattern.         
Max. O D= maximum optical density values.
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DISCUSSION                                                                      
Oxidative injury is a major factor of 
accelerated ageing. It has been sug-
gested that stress induces premature 
senescence, caused by rapid telomere 
shortening resulting from DNA dam-
age including double-strand breaks22, 23. 
Thalassaemia patients are particularly 
at risk of free radical induced dam-
age24 caused by increased generation of 
ROS.2 
Although increased oxidative stress and 
lipid peroxidation (LPO) in thalassemia 
patients have been clearly documented, 
the resulting DNA damage has not yet 
been extensively studied25. In this work 
DNA damage in peripheral leukocytes 
of thalassimic patients was investigated 
depending on the fact that circulating 
leukocytes are surrogate cells which 
continuously maintain a surveillance of 
the body for signs of toxic and antitoxic 
exposures26. The results of this study re-
vealed that the smear shape pattern on 
gel electrophoresis indicating double 
stranded breakage of the DNA confer-
ring fragmentation of extremely vari-
able sizes (confirmed by the chart pat-
tern of Pro-Gel analyzer) was the main 
finding among thalassemic children. 
It occurred in 38 out of the 50 studied 
patients (76%) mainly in the moderate 
(17 out of 50= 34%) and severe form 
(13 out of 50= 26%) (Table 1). The lad-
der pattern denoting apoptosis was not 
detected in any of our thalassemic pa-
tients or the control. All children of the 
control group had normal electropho-
retic pattern. Compared to the control 
group, thlassemic patients (the whole 
group and each of TM and TI group) 
had significantly higher prevalence of 
DNA double -strand breaks in their leu-
kocytes with significant higher values 
of max.O D at 200, 400and 600 bp.
In this regard Offer et al.22 reported 
that relative to healthy control subjects, 
patients with thalassemia exhibited 
elevated levels of DNA damage as re-
flected by an increase in micronuclei 
containing RBCs.
Lymphocytes from thalassemic patients 
were reported to have higher levels of 
both background and induced DNA 
damage particularly DNA stand breaks 
as measured in a comet assay.27  
Elevated LPO-induced adducted DNA 
was found in lymphocytes of thalas-
semic patients and in the liver of thalas-
semic mouse implicating that massive 
DNA damage occurs in the liver of 
these patients.28 
Indirect assessment of DNA damage in 
thalassemic patients have been studied 
by Meerang et al25. who concluded that 
the strongly increased urinary excre-
tion of etheno adducts in the studied 
thalassemic patients indicates elevated 
LPO-induced DNA damage in internal 
organs.
Also, thalassaemic patients had more 
sperm DNA damage than the controls 
(P <0.01).29, 30
Iron plays an important role in oxida-
tive tissue damage31. DNA has also been 
reported to be a target of iron-induced 
damage. Levels of some antioxidants 
are decreased during iron overload32. 
Iron overload is inevitable complica-
tion of thalassemia. About 73% of those 
born with thalassaemia could potential-
ly develop iron overload and toxicity 
from transfusions and/or increased iron 
absorption.8 
In this study serum ferritin was evalu-
ated as a measure of the iron load in 
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the studied thalassemic children. Se-
rum ferritin is the most commonly em-
ployed screening tool and can be used 
effectively to monitor changes in iron 
burden.33 The mean serum ferritin lev-
el of the whole thalassemia group and 
that of each of TM and TI group were 
above 1000ng/ml. The studied thalasse-
mic children (the whole group and each 
of TM and TI groups) had significant 
higher serum ferritin level compared 
to the control group (Table 1). We can 
conclude that significant DNA dam-
age either TGD or the max.OD at 200, 
400 and 600 bp in thalassemic children 
compared to the normal children could 
be attributed to that iron overload. In 
humans, iron overload correlates with 
DNA alterations and cancer.10
The results of this work had revealed 
significant positive correlation between 
the mean serum ferritin levels and the 
values of max. O D at 200 and 400bp 
(Fig. 3) without significant correlation 
to that at 600bp. The bivariate linear 
regression revealed that the mean se-
rum ferritin was more correlated to the 
degree of DNA damage expressed by 
the value of max, OD at 200bp than at 
400bp (p <0.001 and =0.002, respec-
tively). This mean that iron overload 
expressed by high serum ferritin level 
is a risk for more severe degree of DNA 
strand breaks according to data inter-
pretation from the Pro-Gel analyzer 
chart patterns (Fig. 1). In accordance to 
these results, Park et al.34 had concluded 
that iron markedly induced DNA dam-
age in humans and rat leukocytes, de-
noting that these white blood cells are 
sufficiently sensitive to assess exposure 
to iron and the measurement of DNA 
damage in human leucocytes could be 
used as a sensitive biomarker to study 
iron overload in vivo in humans.
Also, Almeida et al35. study results 
showed that iron-mediated lipid per-
oxidation was associated with intense 
mtDNA fragmentation. Perera et al29. 
reported positive association between 
the age of onset of chelation and sperm 
DNA damage and concluded that iron 
overload in thalassemia patients predis-
poses sperm to oxidative injury. 
Serum ferritin concentration predicted 
the urinary excretion rate of 8-hydroxy-
deoxyguanosine a marker of oxidative 
stress, at B= 0.17 (95% CI 0.08-0.26, 
P= 0.001).36  
In agreement of this, Naithani et al37. re-
ported positive correlation between  to-
tal plasma malondialdehyde (as a prod-
uct of LPO) with serum ferritin levels 
of the studied thalassemic patients.
On the other hand Meerang et al28. and 
Cighetti38 reported a negative correla-
tion between plasma malondialdehyde 
and serum ferritin levels in the studied 
patients with thalassemia.
Iron overload is generally defined as se-
rum ferritin consistently >1000 ng/ml39. In 
addition, the critical level of iron over-
load at which toxicity and organ dys-
function occur, or the ‘tipping point’, 
has not been established definitively 
for serum ferritin40. The result of this 
work revealed that at cutoff point of 820 
ng/ml serum ferritin has sensitivity of 
95% and specificity of 75%, for DNA 
damage while it has sensitivity of 76% 
and specificity of 81% for DNA dam-
age at cut off point of 980 ng/ml (Fig. 
4).This means that DNA strand breaks 
occurred at serum ferritin levels below 
and around the defined level of iron 
overload supporting the importance of 
good chelation therapy for thalassemic 
children aiming at keeping their serum 
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ferritin level below 1000ng/ml. The 
previous result came in accordance with 
was reported and recommended that se-
rum ferritin >1000 ng/ml on repeated 
measurements has been proposed as the 
threshold for initiation of iron reduc-
tion therapy in transfusion-dependent 
patients.41, 42
Comparison between the studied thala-
ssemia major and thalassemia interme-
dia patients had revealed non signifi-
cant difference between the two groups 
in the electrophoretic pattern of DNA 
damage or in the values of max.OD at 
200, 400 or 600bp (Table 1). This could 
be attributed to the non significant dif-
ference in the iron load reflected by se-
rum ferritin level between them.
DNA damage and unrepaired strand 
breaks are associated with age-related 
diseases43. Carnitine has been catego-
rized as a conditionally essential nutri-
ent and was found to be beneficial in the 
treatment of deficits associated with the 
aging process44. During the last years, 
L-carnitine was introduced as a safe 
and effective adjunctive therapeutic ap-
proach in thalassemic patients.45 
In this work a subgroup of thalasse-
mic children under regular L-carnitine 
therapy (50mg/kg/d) for at least 6 
months was included. The mean year-
ly serum ferritin level was lower in 
those on than those not on L-carnitine 
therapy (1570±813 versus 1661±769 
ng/ml, respectively), yet the differ-
ence did not reach a significant level. 
The thalassemic children on regular 
L-carnitine therapy had significantly 
lower prevalence and degrees of DNA 
breaks (TGD) with significant lower 
max. OD values at 200, 400 and 600 bp 
compared to those not on L-carnitine 
therapy without significant difference 
in serum ferritin level (Table 1). These 
results denotes that with a matched iron 
load reflected by serum ferritin level, 
L-carnitine therapy had a significant 
protective effect against DNA fragmen-
tation.
In agreement with the results of this 
work, previous studies have demon-
strated that carnitine reacts with su-
peroxide and hydrogen peroxide, has 
reducing properties, chelates iron and 
prevents lipid peroxidation and DNA 
cleavage46,47 L-Carnitine caused a de-
crease in single strand breaks in human 
peripheral blood lymphocytes induced 
by oxygen radicals and alkylating 
agents.48 In aged animals, administra-
tion of L-carnitine for 21 days signifi-
cantly decreased the levels of lipid per-
oxides and improved the activities of 
antioxidant enzymes. It significantly 
reduced DNA damage, apoptosis in 
lymphocytes of these animals.49 The 
therapeutic potential of L-carnitine may 
be related to its antiapoptotic properties 
that had been documented in several 
studies.50-53
Also, the protective effect against DNA 
damage in thalassemic children docu-
mented in this work comes in accor-
dance with and can give an explanation 
for the confirmed beneficial effect of 
L-carnitine supplementation in thalas-
semia patients on several hematologi-
cal and other parameters of health and 
wellbeing that were reported in several 
studies.54-57
In conclusion, thalassemic children had 
significant DNA double-strand breaks 
that was positively correlated to their 
iron overload reflected by serum ferri-
tin level and can be ameliorated by L-
carnitine supplementation. Hence, good 
chelation keeping the serum ferritin 
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level below 1000ng/ml and L-carnitine 
supplementation are recommended for 
thalassemic children. 
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